BioSpace News Archive

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.

Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST.

Halozyme Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021, and recent operational highlights.

Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31, 2021.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.

Cerus Corporation announced financial results for the fourth quarter and full year ended December 31, 2021.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the fourth quarter and year ended December 31, 2021 and corporate highlights.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, reported its financial results for the quarter and year ended December 31, 2021 and financial guidance for the year ending December 31, 2022.